Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice
© 2013 Katzav et al.; licensee BioMed Central Ltd. 2013
Received: 18 October 2012
Accepted: 31 January 2013
Published: 4 April 2013
We investigated interactions between genetically and autoimmune-mediated coagulopathies by inducing experimental antiphospholipid syndrome (eAPS) in mice carrying the factor V Leiden (FVL) mutation.
eAPS was induced in heterozygous and homozygous FVL transgenic mice (C57BL/6 background) by immunization with β2-glycoprotein I (β2-GPI). Autoantibody levels were measured at 1 and 5 months post-immunization. Mice were tested at 4 months post-immunization for behavior and cognitive function in the staircase, elevated plus-maze, and swim T-maze tests. Brains were removed and analyzed by immunohistochemistry for inflammatory markers and neurodegenerative processes.
A single immunization with β2-GPI induced significantly higher and longer-lasting immune responses, and this was dependent on the number of FVL alleles. At 1 and 5 months post-immunization, levels of antibodies rose from 1.17 ± 0.07 to 1.62 ± 0.17 (optical density units; ODU) in homozygous FVL mice, compared with stable levels of 0.59 ± 0.17 and 0.48 ± 0.16 ODU in heterozygous FVL mice and a drop from 1.62 ± 0.21 to 0.61 ± 0.13 ODU in wild-type mice. Behavioral and cognitive clinical features of eAPS were also correlated with FVL allele load, as assessed by the elevated plus-maze (altered anxiety), staircase (hyperactivity and higher exploration), and swim T-maze (impaired learning) tests. Histological studies identified significant neurodegenerative changes in both grey and white matter in the eAPS-FVL brains. In spite of the potential interaction of two prothrombotic disease states, there were no ischemic lesions seen in this group.
The results indicate that genetically mediated coagulopathies increase the risk of developing coagulation-targeted autoimmune responses, and suggest the importance of antibody-mediated neurodegenerative processes in the brain in APS.
KeywordsAutoimmunity Coagulopathy Antiphospholipid syndrome Factor V leiden Experimental antiphospholipid syndrome Autoantibodies Hyperactivity Cognitive dysfunction Neurodegeneration
Blood coagulation factor V (FV) is a pivotal protein in hemostasis, playing a crucial role in both the procoagulant and anticoagulant pathways [1, 2]. FV serves as a cofactor of factor Xa in the prothrombinase complex that converts prothrombin to active thrombin. FV is inactivated by activated protein C (APC). FV Leiden (FVL) is a genetically acquired trait that can result in a thrombophilic (hyprcoaguable) state, resulting in the phenomenon of APC resistance. The FVL allele is present in about 5% of Caucasian populations (European, Jewish, Israeli Arab, and South Asian (Indian) populations) and is virtually absent in Africans and East Asian populations [3, 4]. FVL is the most common cause of inherited thrombosis, accounting for 40-50% of cases .
Antiphospholipid syndrome (APS) is the most important acquired thrombophilic defect. APS is characterized by the presence of anti-phospholipid (aPL) antibodies and by occurrence of clinical features including repeated spontaneous abortions, thrombocytopenia, systemic thrombosis, and central nervous system (CNS) dysfunction. aPL antibodies are a heterogeneous group of circulating autoantibodies directed against negatively charged phospholipids and phospholipid-binding proteins, such as β2-glycoprotein I (β2-GPI) and prothrombin . Because thrombosis does not occur in all patients with aPL antibodies, it is likely that additional factor(s) determine the clinical presentations of APS. An association of FVL and APS has been reported previously [6–8], and this coexistence of APS and FVL has been hypothesized to occur by chance and to increase the risk of thrombosis . aPL antibodies have been found to inhibit APC anticoagulant function and cause acquired APC resistance [10–15]. However, there are few epidemiological data available about the prevalence of aPL antibodies in subjects with and those without FVL.
We have developed a consistent and reproducible animal model of the CNS effects of APS [16, 17]. This model is induced in female mice by immunization with the autoantigen β2-GPI. Following a single immunization, these mice develop sustained high levels of autoantibodies to phospholipids and over a period of 4–5 months, the mice display significant behavioral changes and cognitive deficits. A knock-in transgenic model of FVL has been developed by Ginsburg et al. ; these mice are prothrombotic but otherwise phenotypically normal.
In the present study, we examined the interaction of APS with FVL using our mouse model to investigate whether there is an increased risk of thrombosis and exacerbation of the experimental APS (eAPS) phenotype. The results indicated that there is a significant enhancement of both APS linked antibodies and brain dysfunction but unexpectedly, without significant ischemic pathology.
The Tel Aviv University Animal Welfare Committee approved all procedures.
The transgenic mice used in this study (kindly provided by Professor David Ginsburg, University of Michigan, Ann Arbor, MI, USA) carry the ortholog of the human FVL mutation previously generated by a knock-in of the R504Q mutation into the endogenous murine factor V locus by homologous recombination . These mice were back-crossed to C57BL/6 mice for more than seven generations. Genotyping of the offspring for the FVL transgene was performed by PCR with previously described primers, using DNA obtained from tail biopsies taken post-weaning. The mice were raised under standard conditions, 23 ± 1°C, 12 -hour light cycle (0700 to 1900 hours) with ad libitum access to food and water.
Preparation of β2-GPI
Human plasma was used as a source of β2-GPI by the method of Polz et al. . In brief, serum proteins were precipitated by perchloric acid, and the remaining supernatant was adjusted to pH 8 by adding a saturated Na2CO3 solution. This fraction was dialysed exhaustively against 0.03 M NaCI pH 8 at 4°C, and further purified by affinity chromatography on heparin column (HiTrap Heparin HP, GE Healthcare Life Sciences, UK). Fractions containing β2-GPI were eluted with 0.35 mol/l NaCl, then separated by protein electrophoresis and visualized with silver stain. Fractions used for immunization contained a major band that was shown by western blotting to cross-react with a commercial antibody to β2-GPI (anti-ApoH; CSL Behring, Marburg, Germany) .
Induction of experimental antiphospholipid syndrome
Mice heterozygous (FVLQ/+) and homozygous (FVLQ/Q) for the FVL transgene were immunized by a single intradermal injection with 10 μg of β2-GPI emulsified in complete Freund’s adjuvant (CFA). The control group comprised FVLQ/+ mice immunized similarly with CFA. C57BL/6 mice were immunized with either β2-GPI in CFA or CFA alone.
In the first experiment, both female and male FVLQ/+ mice were divided into two groups of fifteen each. Each group included seven to eight mice immunized with β2-GPI (eAPS mice), and seven to eight mice immunized with CFA (adjuvant-immunized controls). In the second experiment, female FVLQ/Q mice (n = 7) were immunized with β2-GPI, and female FVLQ/+ mice (n = 8) were immunized with CFA. Mice were immunized at 3 to 4 months of age, and behavioral assessment was started 4 months later with the staircase test, followed by the elevated plus-maze test and the swim T-maze test on the following sequential days.
For serological evaluation, blood samples were collected from all the mice described above at 1 and 5 months after immunization. Autoantibody measurements were additionally performed in naive FVLQ/+ mice (n = 7), and naive C57BL/6 mice (n = 9). Autoantibody levels in these experiments were also compared with those in C57BL/6 mice with experimental APS induction (n = 10 and n = 11 for C57/B6-APS and C57/B6-control mice, respectively).
Blood samples were collected by retro-orbital sinus puncture as soon as the mice completed their behavioral and cognitive assessment. The sera were separated by centrifugation and stored at −70°C until assayed. The sera were tested by standard ELISA for the presence of autoantibodies as previously described , using serum-dependent (β2-GPI) and serum-independent antibodies to cardiolipin (CL) and phosphatidylserine, and antibodies to β2-GPI and double-stranded DNA.
The staircase apparatus consisted of a polyvinylchloride (PVC) enclosure with five identical steps, 75 × 100 × 25 mm, on top of each other. The inner height of the walls above the level of the stairs was consistent (125 mm) along the whole length of the staircase. The box was placed in a room with constant lighting and isolated from external noise. Each mouse was tested individually. The animal was placed on the floor of the staircase with its back to the staircase. The number of stairs climbed and the number of rears during a 3-minute period were recorded. Climbing was defined as each stair on which the mouse placed all four paws; rearing was defined as each instance the mouse rose on hind legs (to sniff the air), either on a stair or leaning against the wall. The number of stairs descended was not taken into account. Before each test, the box was cleaned with a diluted alcohol solution to eliminate smells.
A three-arm, walled T-maze,constructed of white Plexiglas (600 mm along the stem, 800 mm side at the T-intersection, 400 mm high, with passages 100 mm wide), was situated in one corner of a brightly lit behavioral-testing room separate from the colony. The T-maze was refilled daily with 145 mm of water at 2°C so that a platform (140 mm high, 300 mm2 in size), rising from the floor of the maze, was submerged 5 mm below the water line. One day prior to initial training, mice were placed in the maze and allowed to swim for 60 seconds with no platform present. The platform was then inserted in a standardized position 80 mm from the end of a goal arm, and each mouse was placed directly on the platform for 30 seconds. Finally, each mouse was placed at the far end of the stem and allowed to locate the submerged goal-arm platform. On each of four consecutive training days, a forced-choice alternation paradigm required each subject to perform eight replications of a paired forced-choice/free-choice trial sequence. With either the left or right goal arm blocked with a guillotine door, each subject was placed in the far end of the stem, and allowed to ascend the submerged platform located in the goal arm opposite the blocked arm. The animal remained atop the platform for 15 seconds at the conclusion of this forced choice trial. The animal was then removed by the tail and again placed at the end of the stem, while simultaneously, the guillotine door was removed and the platform moved to the opposite goal arm; that is, the one previously blocked. The latency period for the mouse to reach the platform and the number of correct choices, defined as entry into the goal arm with a platform prior to entry into the goal arm without a platform or re-entry into the stem, were measured during these free-choice trials. Each subject was again allowed to remain on the platform for 15 seconds and was then replaced in the home cage. The goal arm designated for forced choice (right or left hand) alternated from trial to trial over the eight trials of a daily session, from animal to animal over the course of a single day’s testing, and from day to day in terms of trial 1. Subjects who failed to locate the platform within 1 minute were assigned a latency of 60 seconds, lifted from the water by the tail, and placed atop the platform. The results were analyzed as the percentage of correct choices, using repeated-measures ANOVA.
Elevated plus-maze test
The elevated plus maze was made from polyvinylchloride, and built in the shape of a plus sign, with two open (white) arms (340 × 75 × 10 mm) and two closed (black) arms (340 × 75 × 175 mm) opposite each other. The center of the four arms comprised the middle square (75 × 75 mm). The maze was elevated 510 mm above ground level. Each mouse was placed separately in the centre of the maze, facing an open arm, and allowed to explore the apparatus freely for 5 minutes. Parameters measured included the number of entries into the closed and open arms (an index of motor function), and the length of time spent in the closed and open arms. An entry was counted only after the mouse entered the arm with four paws. Before each test, the box was cleaned with a diluted alcohol solution to eliminate smells. The percentage of entries into the open arms out of the total number of arm entries and the percentage of time spent in the open arms, which are all accepted measures of anxiety levels, were further calculated.
Mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (20 mg/kg) and underwent transcardiac perfusion with phosphate buffer saline followed by perfusion with 4% paraformaldehyde in PBS. Brain tissue was collected, fixed in 4% paraformaldehyde and embedded in paraffin wax. Coronal sections 6 μm thick were cut, mounted, and stained with hematoxylin and eosin (H&E), Luxol Fast Blue (LFB), and Bielchowsky (BLS) stains to identify histological details and the density of myelin and axons, and the sections were specifically examined to evaluate ischemic pathology such as micro-infarcts.
Paraffin wax-embedded sections were dewaxed and rehydrated in xylene and alcohol solutions, then rinsed with PBS. Citrate buffer was used for antigen retrieval, and endogenous peroxidase was blocked with 3% H2O2 in methanol. After incubation of the sections in blocking buffer (Foetal bovine serum, FBS) they were treated with primary antibodies against glial acidic fibrillary protein (GFAP; Dako, Glostrup, Denmark), MAC3, B220 (both BD Biosciences, Inc., San Jose, CA, USA), CD3 (Neomarkers Inc., Fremont, CA, USA), vascular endothelial growth factor (VEGF; Spring Bioscience Corp., Pleasanton, CA, USA), for the detection of astrocytes, macrophage/microglia, B cells, T cells, and VEGF, respectively (dilutions: 1;500, 1:100, 1:100, 1:150, 1:100, respectively). Immunoreactivity was visualized with a commercial system (EnVision HRP; Dako) and sheep anti–rat antibody (AbD Serotec, Raleigh, NC, USA). DAB (Sigma Chemical Co., St Louis, MO, USA) was used as chromogen. Counterstaining was performed with hematoxylin.
Immunofluorescence staining for Iba1 (rabbit polyclonal antibody, Wako, Osaka, Japan) was used to identify microglial and macrophage populations, and was performed using the same protocol as described above with the appropriate secondary antibody (goat anti-rabbit IgG conjugated to fluorescein isothiocyanate (AlexaFluor 488). Slides were mounted with DAPI (Invitrogen Corp., Carlsbad, CA, USA).
In vitroimmunohistological staining
We investigated which specific brain structures the aPL antibodies bind to, using brain sections of normal mice immunostained with pooled serum from FVL-eAPS and control mice. Normal brain sections were stained with pooled serum (diluted 1:200) overnight at 4°C and then with the secondary antibody (alkaline phosphatase conjugated anti-mouse IgG). Bound antibody was detected by development with Fast Red substrate (Sigma Chemical Co.) for 10 minutes, after which the sections were mounted with glycerol.
Sections were examined using fluorescence and optical microscopy (Axioplan-2; Carl Zeiss, Jena, German) with the aid of a CCD camera (DS-5Mc; Nikon, Tokyo, Japan) by two independent observers blinded to the experimental groups. The evaluation was performed for the whole brain, using the Paxinos and Franklin (2004) stereotaxic coordinates (ranging from bregma 2.22 to bregma −6.36) . On average, 20 optical fields per slice and three slides per each group were examined under × 20 or × 40 magnification. Measurements were performed with ImageJ software (version 1.43; http://rsb.info.nih.gov/ij/), and data are presented as positive cells per mm2 for MAC3, CD3, B22O, VEGF, and GFAP. Additional evaluation for astrocytic and microglial activation was performed as the ratio of tissue area positive for GFAP/Iba1 per mm2 of total area studied. The density of myelin and axons was evaluated with Image J software, using a range of 0.05 to 3.05 OD units, and measurements were performed using a Rodbard function.
Levels of antibodies and scores on the staircase and plus-maze tests were compared using one-way ANOVA followed by least squares difference post hoc tests. Performance on the swim T-maze was analyzed by means of repeated-measures ANOVA. Most statistical tests were performed using the SPSS software package for PC (SPSS Inc., Chicago, IL, USA). Statistical analysis of histological data was performed using GraphPad Prism software (version 5.0, GraphPad Software, La Jolla, CA, USA). The normality was tested using the Shapiro-Wilk and Kolmogorov-Smirnov tests. Non-parametric data were analyzed using the equivalent Kruskal-Wallis test followed by Dunn’s post hoc multiple-comparison test. Values of all scale data are expressed as mean ± SE. All determinations were made with 95% confidence interval and were considered significant at P < 0.05.
Antiphospholipid autoantibody levels are increased in eAPS-FVL mice
The effect of sex on autoantibodies in FVLQ/+ APS mice was also examined. One month after immunization, both female and male FVLQ/+ APS mice developed high levels of anti-CL(β2-GPI) (0.59 ± 0.17 and 0.30 ± 0.14 ODU, respectively) compared with their FVL adjuvant-immunized controls (0.02 ± 0.002 and 0.02 ± 0.003 ODU, respectively), and there was no significant difference between the sexes (P = 0.001 for immunization effect and P = 0.28 for sex effect, ANOVA). However, 4 months later (that is, 5 months post-immunization), the level of anti-CL(β2-GPI) was significantly higher in the female(0.48 ± 0.16) than in the male (0.21 ± 0.08) FVL-APS mice, (P = 0.037 for sex effect, ANOVA).
Functional brain changes in FVL-APS mice
The results of the elevated plus-maze test are presented as the mean percentage time spent in the white (open) arms (Figure 2B). Both the FVLQ/+-APS and FVLQ/Q-APS mice spent significantly more time in the white arms compared with the FVL-CFA controls (P < 0.031 by ANOVA), indicating altered levels of anxiety induced by APS in FVL mice.
Behavioral measurements in the staircase test included activity and exploration (Figure 3). The results are presented as the mean number of events relative to the appropriate control group of wild-type (C57BL/6) or FVL mice (= 100%). In the activity measure (stair-climbing; Figure 3A), FVLQ/+-APS and FVLQ/Q-APS mice were hyperactive compared with their FVLQ/+ controls (FVL control, P < 0.035 for the effect of immunization) and with FVL+/+-APS mice, which were hypoactive relative to their wild-type controls. In the exploratory measure (rearing; Figure 3B), the FVLQ/Q-APS mice had significantly higher levels of exploration compared with the FVLQ/+-CFA controls, whereas no significant difference was found between the FVLQ/+-APS and the FVLQ/+-CFA controls (P < 0.001 and P = 0.26, respectively).
Only two clinically overt stroke incidents occurred, which were both in the first group of animals examined. These were a right middle cerebral artery (MCA) ischemic event and a venous thrombosis, which occurred spontaneously in FVLQ/+ mice 1 week after immunization with β2-GPI. The strokes were identified when the animals developed severe motor signs and were hemiplegic or obtunded. The diagnosis was verified by macroscopic examination and magnetic resonance imaging scans of the brains. The other mice did not display any focal motor weakness throughout the study period.
Histology studies show mainly neurodegenerative changes
In vitrostaining with pooled mouse IgG
In the present study, the main findings were an increase in aPL antibody levels and a number of behavioral/cognitive dysfunction and neurodegenerative changes associated with these autoantibodies in the FVL eAPS mice. These effects were linked to gene dosage, and were thus significantly more pronounced in homozygous FVLQ/Q than in heterozygous FVLQ/+ mice. The serological and behavioral effects found in the FVL mice in this study are in line with results of previous studies using other mouse strains in which eAPS was induced by immunization with β2-GPI [17, 23, 24] or immunization with a pathogenic autoantibody .
The pathogenesis of aPL antibody-mediated brain damage is complex, and may include thrombosis, inflammation, or direct binding of antibodies to the brain. The results of the present study do not support the presence of either thrombosis or inflammation in the FVL eAPS brain. This is in line with previous studies in the eAPS model in various wild-type strains of mice, including C57BL/6 [26, 27]. It is also compatible with findings in human APS, as a significant number of patients with neurological features do not have imaging or clinical findings supporting thrombosis or brain inflammation [28, 29].
In view of the lack of thrombosis or inflammation, the most significant pathogenic factor explaining the interaction of FVL and APS are the very high levels of aPL antibodies. The levels of these antibodies in β2-GPI-immunized wild-type C57BL/6 mice are known to decline significantly over time [17, 23], which is in contrast to the continuing increase seen in the homozygous FVLQ/Q mice and in the stable levels found in the heterozygous FVLQ/+ mice in the current study. It should be stressed that all β2-GPI-immunized eAPS mice in the present study received only one immunization, and that the response in FVL mice is unusually strong and prolonged compared to the response in C57BL/6 mice . These very high levels of aPL antibodies correlate with the behavioral and cognitive deficits, which are not found in wild-type C57BL/6 eAPS mice , and indeed induction of APS in wild-type C57BL/6 mice causes hypoactivity rather than the hyperactivity seen in the FVL mice. These findings suggest that the brain is affected by antibodies in a manner not mediated primarily through thrombosis or inflammation. A major potential pathogenic mechanism is the direct binding of aPL antibodies to brain cells such as neurons, and subsequent specific dysfunction of these cells. This mechanism is well established in diseases such as myasthenia gravis and Lambert-Eaton myasthenic syndrome , and in CNS autoimmune diseases such as the anti-potassium channel antibody spectrum and paraneoplastic autoimmune diseases [31, 32]. We have shown previously that APS  and eAPS sera  do bind to neurons in specific limbic areas of the normal mouse brain. In the present study, we found specific binding of IgG from FVL-APS mice to normal brain, mainly to neurons in the white-matter area of the hippocampus and cortex. This binding was more pronounced in the FVLQ/Q-APS than the FVLQ/+-APS mice, and was not seen with sera of the adjuvant-immunized control FVL mice. This supports our suggestion that binding of IgG directly to the brain may be a major pathogenic mechanism in these mice.
The potential effects of direct binding of antibodies to the mouse brain are neuronal dysfunction and death, which would essentially lead to a neurodegenerative process. Neurodegeneration is indeed supported by the histological results in the present study, with both neuronal cell-body loss and axon loss seen in the FVL eAPS mice in a gene-dose/antibody-level-dependent fashion. The increased microglial activation in FVL eAPS mice is probably best explained as a secondary response to neurodegenerative changes, as this was not accompanied by changes in astrocytes or by overt inflammation with changes in astrocytes, macrophages, or lymphocytes. This finding again suggests that neurodegenerative processes in human APS may well be explained by high aPL antibody levels.
A trend towards a, FVL gene-dose-dependent exaggerated response to immunization was found in the eAPS mice. The finding that the wild-type FVL+/+ mice had the highest initial levels of aPL antibodies at 1 month indicates that expression of the gene does not have an immediate stimulatory effect on the immune system. It was at the later time point (5 months) that aPL antibody levels were increased in the FVLQ/+ mice, and this effect was dramatically more pronounced in the FVLQ/Q mice. The most reasonable explanation for this late and prolonged elevation of aPL antibody levels in FVLQ/Q mice is that of an ongoing process, such as the chronic exposure of the immune system to activated components of the clotting system, which include β2-GPI. This is in line with our recent publication describing spontaneous development of specific pathogenic aPL (β2GPI-dependent) autoantibodies in genetically hypercoagulation-prone FVL mice immunized with adjuvant alone . Interestingly, adjuvant-immunized FVL mice exhibited hyperactivity behavior compared with non-immunized FVL mice, which correlated with the autoantibody level . These results are in line with the hyperactivity behavior displayed in an experimental APS model induced in naive strains [16, 17, 23, 27], in a transgenic mouse model of Alzheimer’s disease , and in transgenic FVL mice (the present study).
We therefore propose the following hypothesis for the mechanism of specific generation of pathogenic aPL antibodies in FVL mice. Autoantibodies to coagulation factors and associated proteins are commonly described in patients with APS [36, 37], and β2-GPI itself is intimatelyassociated with the coagulation process. In a situation such as FVL, in which there is chronic uncontrolled coagulation, the immune system is continuously exposed to antigens altered by and specifically associated with coagulation. This is analogous to the antibodies generated by exposure to high levels of apoptotic cells generated in animals with deficiencies of clearance, such as complement deficiency and Fas deficiency or in cancer, conditions that are strongly associated with autoimmunity. This hypothesis suggests that the clinical association of FVL and APS is not merely a coincidence, but that chronic coagulation defects combined with external inflammatory stimuli analogous to adjuvant may induce aPL antibodies and also APS. We suggest therefore that chronic coagulation defects should be added to apoptotic-cell-clearance defects, cancer, and infection as significant factors leading to autoimmunity. The hypothesis would explain the linkage of APS with FVL found in a familial study . It would also predict that in humans, the FVL genotype is likely to be associated with higher levels of aPL and perhaps also APS. One report has indeed found increased levels of aPL antibodies in women with FVL taking oral contraception . Another report presented detailed tables of the data from which it was possible to calculate the proportion of APS markers in large groups of patients with FVL compared with normal controls . Using Table 6 of that publication, it is possible to calculate the association of lupus anticoagulant (LA) with FVL both in women with recurrent pregnancy loss and in controls, and this association was highly significant for both groups (χ2 test, P = 1.4 × 10-6, for the combined groups: 26 LA-positive women out of 43 women with FVL, compared with 46 LA-positive women out of 209 controls). By contrast, some investigators have found a reverse relationship between APS and FVL . in a group of women with history of miscarriage and a group of patients with APS, no association was identified between FVL and aPL antibodies [42–44]. There were a number of methodological (selection bias) or molecular mechanisms that may explain this discrepancy. Prospective clinical studies are indicated to definitively examine the prevalence of APS and aPL antibodies in FVL carriers.
The coagulation-induced autoimmunity hypothesis implies that generation of aPL antibodies in human APS may involve a positive feedback loop, in which procoagulant antibodies generate hypercoagulation, which exposes the immune system to more antigens, consolidating the pathogenic immune response and leading to antigen spread. The therapeutic implication of this hypothesis is that anticoagulant therapy may also have an immunologic effect in APS and contribute to lowering of aPL antibody levels. This hypothesis would also predict that high levels of aPL antibodies would be difficult to induce by β2-GPI immunization in β2-GPI-deficient mice. In addition, the results of the present study indicate that aPL antibody levels are a significant factor in causing neurodegeneration, and should be targeted directly by therapy.
Activated protein C
Complete freund’s adjuvant
Central nervous system
Experimental antiphospholipid syndrome
Enzyme-linked immunosorbent assay
Factor V leiden
Luxol fast blue staining
This research was supported by The Israel Science Foundation (grant number 917/08). This work was performed in partial fulfillment of the requirements for a PhD degree for AK (Sackler Faculty of Medicine, Tel Aviv University, Israel).
- Rosendorff A, Dorfman DM: Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med. 2007, 131: 866-871.PubMedGoogle Scholar
- Segers K, Dahlback B, Nicolaes GA: Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007, 98: 530-542.PubMedGoogle Scholar
- De Stefano V, Chiusolo P, Paciaroni K, Leone G: Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost. 1998, 24: 367-379.View ArticlePubMedGoogle Scholar
- Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet. 1995, 346: 1133-1134.View ArticlePubMedGoogle Scholar
- Biggioggero M, Meroni PL: The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010, 9: A299-A304.View ArticlePubMedGoogle Scholar
- Diz-Kucukkaya R, Demir K, Yenerel MN, Nalcaci M, Kaymakoglu S, Inanc M: Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome. Haematologia (Budap). 2002, 32: 73-77.View ArticleGoogle Scholar
- Picillo U, De Lucia D, Palatiello E, Scuotto A, Marcialis MR, Pezzella S, Tirri G: Association of primary antiphospholipid syndrome with inherited activated protein C resistance. J Rheumatol. 1998, 25: 1232-1234.PubMedGoogle Scholar
- Schutt M, Kluter H, Wiedemann GJ, Richardt G: Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia. Z Kardiol. 2000, 89: 1067-1071.View ArticlePubMedGoogle Scholar
- Kaiser R, Barton JL, Chang M, Catanese JJ, Li Y, Begovich AB, Criswell LA: Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun. 2009, 10: 495-502.View ArticlePubMedPubMed CentralGoogle Scholar
- Alarcon-Segovia D, Ruiz-Arguelles GJ, Garces-Eisele J, Ruiz-Arguelles A: Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. J Rheumatol. 1996, 23: 2162-2165.PubMedGoogle Scholar
- Aznar J, Villa P, Espana F, Estelles A, Grancha S, Falco C: Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med. 1997, 130: 202-208.View ArticlePubMedGoogle Scholar
- Bokarewa MI, Bremme K: Production of phospholipid antibodies in selected thrombophilic women differing in genotype at the 506 site of factor V. Eur J Haematol. 1998, 61: 21-26.View ArticlePubMedGoogle Scholar
- Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y: Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem. 2005, 51: 545-552.View ArticlePubMedGoogle Scholar
- Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A: Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis. 1996, 7: 344-348.View ArticlePubMedGoogle Scholar
- Viveros ME, Cabiedes J, Reyes E, Cabral AR: Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies. Rev Invest Clin. 2005, 57: 563-571.PubMedGoogle Scholar
- Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, Chapman J: Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001, 10: 496-499.View ArticlePubMedGoogle Scholar
- Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, Blank M, Zaech J, Shoenfeld Y, Sirota P, Chapman J: Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus. 2002, 11: 736-743.View ArticlePubMedGoogle Scholar
- Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D: Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000, 96: 4222-4226.PubMedGoogle Scholar
- Polz E, Wurm H, Kostner GM: Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem. 1980, 11: 265-270.View ArticlePubMedGoogle Scholar
- Ball-Rosen C, Primak-Rubinovicz H, Korczyn AD, Wang N, Farchi A, Shavit S, Shoenfeld Y, Chapman J: Identification of histidine-rich glycoprotein, a potential autoantigen, in human and rat brain preparations. Ann N Y Acad Sci. 2007, 1109: 473-483.View ArticlePubMedGoogle Scholar
- Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y: Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest. 1992, 89: 1558-1563.View ArticlePubMedPubMed CentralGoogle Scholar
- Paxinos G, Franklin KBJ: The mouse brain in stereotaxic coordinates. 2004, San Diego: AcademicGoogle Scholar
- Katzav A, Litvinjuk Y, Pick CG, Blank M, Shoenfeld Y, Sirota P, Chapman J: Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res. 2006, 169: 289-293.View ArticlePubMedGoogle Scholar
- Katzav A, Shoenfeld Y, Chapman J: The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol. 2010, 38: 196-200.View ArticlePubMedGoogle Scholar
- Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD: Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest. 1997, 100: 613-619.View ArticlePubMedPubMed CentralGoogle Scholar
- Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, Pick CG, Shoenfeld Y, Korczyn AD, Chapman J: Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging. 2011, 32: 272-279.View ArticlePubMedGoogle Scholar
- Tanne D, Katzav A, Beilin O, Grigoriadis NC, Blank M, Pick CG, Landenberg P, Shoenfeld Y, Chapman J: Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol Dis. 2008, 30: 56-64.View ArticlePubMedGoogle Scholar
- Chapman J, Abu-Katash M, Inzelberg R, Yust I, Neufeld MY, Vardinon N, Treves TA, Korczyn AD: Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci. 2002, 203–204: 81-84.View ArticlePubMedGoogle Scholar
- Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J: Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000, 11: 36-38.View ArticlePubMedGoogle Scholar
- Lang B, Vincent A: Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev. 2003, 2: 94-100.View ArticlePubMedGoogle Scholar
- Dalmau J, Rosenfeld MR: Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008, 7: 327-340.View ArticlePubMedPubMed CentralGoogle Scholar
- Irani SR, Vincent A: Autoimmune encephalitis – new awareness, challenging questions. Discov Med. 2011, 11: 449-458.PubMedGoogle Scholar
- Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, Pick CG, Leider-Trejo L, Kalashnikova L, Blank M, Chapman J: Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus. 2003, 12: 436-442.View ArticlePubMedGoogle Scholar
- Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J: Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012, 21: 210-216.View ArticlePubMedGoogle Scholar
- Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, Pick CG, Shoenfeld Y, Korczyn AD, Chapman J: Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiology of Aging. 2011, 32: 272-279.View ArticlePubMedGoogle Scholar
- Kalashnikova LA, Korczyn AD, Shavit S, Rebrova O, Reshetnyak T, Chapman J: Antibodies to prothrombin in patients with Sneddon’s syndrome. Neurology. 1999, 53: 223-225.View ArticlePubMedGoogle Scholar
- Todorova M, Baleva M: Some recent insights into the prothrombogenic mechanisms of antiphospholipid antibodies. Curr Med Chem. 2007, 14: 811-826.View ArticlePubMedGoogle Scholar
- Schutt M, Kluter H, Hagedorn-Greiwe M, Fehm HL, Wiedemann GJ: Familial coexistence of primary antiphospholipid syndrome and factor VLeiden. Lupus. 1998, 7: 176-182.View ArticlePubMedGoogle Scholar
- Poka R, Vad S, Lakos G, Bereczki Z, Kiss E, Sipka S: Increased titer of anti-beta2-glycoprotein I IgG antibody among factor V Leiden carriers during oral contraceptive use. Contraception. 2004, 69: 27-30.View ArticlePubMedGoogle Scholar
- Mtiraoui N, Borgi L, Hizem S, Nsiri B, Finan RR, Gris JC, Almawi WY, Mahjoub T: Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol. 2005, 119: 164-170.View ArticlePubMedGoogle Scholar
- Besnier R, Frances C, Ankri A, Aiach M, Piette JC: Factor V Leiden mutation in Sneddon syndrome. Lupus. 2003, 12: 406-408.View ArticlePubMedGoogle Scholar
- Dizon-Townson D, Hutchison C, Silver R, Branch DW, Ward K: The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost. 1995, 74: 1029-1031.PubMedGoogle Scholar
- Pablos JL, Caliz RA, Carreira PE, Atsumi T, Serrano L, Amengual O, Santiago B, Khamashta MA, Hughes GR, Gomez-Reino JJ: Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol. 1999, 26: 588-590.PubMedGoogle Scholar
- Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, Regan L: Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod. 2001, 16: 961-965.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/11/92/prepub